MX2009002314A - Composiciones farmaceuticas que comprenden hgh para suministro oral. - Google Patents

Composiciones farmaceuticas que comprenden hgh para suministro oral.

Info

Publication number
MX2009002314A
MX2009002314A MX2009002314A MX2009002314A MX2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A
Authority
MX
Mexico
Prior art keywords
growth hormone
human growth
hgh
pharmaceutical compositions
oral delivery
Prior art date
Application number
MX2009002314A
Other languages
English (en)
Inventor
Moise Azria
Yatindra Joshi
Rosario Lobrutto
Linda Mindeholm
Ashish Bipin Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009002314A publication Critical patent/MX2009002314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas de dosificación de la hormona de crecimiento humana, el uso de un aumentador de absorción para permitir la absorción de la hormona de crecimiento humana en la circulación sistémica en una forma biológicamente activa, en particular una administración oral, así como el uso de las formas de dosificación oral que comprenden la hormona de crecimiento humana y un aumentador de absorción para el tratamiento de las deficiencias de la hormona de crecimiento humana y desordenes saciados con la misma.
MX2009002314A 2006-08-31 2007-08-28 Composiciones farmaceuticas que comprenden hgh para suministro oral. MX2009002314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82414006P 2006-08-31 2006-08-31
PCT/US2007/076932 WO2008027854A2 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hgh for oral delivery

Publications (1)

Publication Number Publication Date
MX2009002314A true MX2009002314A (es) 2009-03-20

Family

ID=39000473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002314A MX2009002314A (es) 2006-08-31 2007-08-28 Composiciones farmaceuticas que comprenden hgh para suministro oral.

Country Status (14)

Country Link
US (1) US8323688B2 (es)
EP (1) EP2059260B1 (es)
JP (1) JP5042312B2 (es)
KR (1) KR101524880B1 (es)
CN (2) CN101557827A (es)
AU (1) AU2007289344B2 (es)
BR (1) BRPI0716261A2 (es)
CA (1) CA2661521C (es)
ES (1) ES2426485T3 (es)
MX (1) MX2009002314A (es)
PL (1) PL2059260T3 (es)
PT (1) PT2059260E (es)
RU (1) RU2493868C2 (es)
WO (1) WO2008027854A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
WO2008112836A2 (en) * 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
PE20151205A1 (es) 2008-08-15 2015-08-31 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
RU2539797C2 (ru) 2009-01-22 2015-01-27 Ново Нордиск Хелс Кеа Аг Производное гормона роста человека с повышенной стабильностью к протеолитическому разрушению, способ получения такого производного, его применение, способ лечения и фармацевтическая композиция
SG10201704777RA (en) * 2009-06-08 2017-07-28 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
EA201290799A1 (ru) 2010-02-17 2013-03-29 Айронвуд Фармасьютикалз, Инк. Лечение желудочно-кишечных расстройств
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
WO2013025969A1 (en) 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
PL3416677T3 (pl) * 2016-02-17 2022-11-21 Genexine, Inc. Kompozycja farmaceutyczna obejmująca rekombinowany hgh do leczenia niedoboru hormonu wzrostu

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PL184531B1 (pl) * 1995-06-07 2002-11-29 Alkermes Inc Kompozycja o opóźnionym uwalnianiu ludzkiego hormonu wzrostu do wytwarzania leku do terapii
EP0993831B1 (en) * 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK1007085T3 (da) * 1997-07-04 2002-05-13 Pharmacia Ab Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
DE60233803D1 (de) * 2001-08-17 2009-11-05 Novartis Ag 5-cnac zur oralen verabreichung von parathormonfragmenten
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
DK1581251T3 (da) * 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
AU2004255458B2 (en) 2003-07-11 2007-09-13 Emisphere Technologies, Inc. Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
PT1651249E (pt) 2003-07-23 2012-12-21 Novartis Ag Uso de calcitonina em osteoartrite
WO2005027894A1 (en) * 2003-09-19 2005-03-31 Pfizer Health Ab Enhanced method of treatment of growth disorders
US8030271B2 (en) * 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
CN105641686A (zh) * 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形

Also Published As

Publication number Publication date
AU2007289344A1 (en) 2008-03-06
RU2493868C2 (ru) 2013-09-27
BRPI0716261A2 (pt) 2013-08-06
EP2059260A2 (en) 2009-05-20
US20100247608A1 (en) 2010-09-30
AU2007289344B2 (en) 2011-04-14
KR20090045416A (ko) 2009-05-07
PT2059260E (pt) 2013-09-03
ES2426485T3 (es) 2013-10-23
US8323688B2 (en) 2012-12-04
CA2661521C (en) 2016-04-12
JP5042312B2 (ja) 2012-10-03
CN101557827A (zh) 2009-10-14
WO2008027854A3 (en) 2008-07-03
JP2010502639A (ja) 2010-01-28
PL2059260T3 (pl) 2014-03-31
WO2008027854A2 (en) 2008-03-06
EP2059260B1 (en) 2013-06-19
CA2661521A1 (en) 2008-03-06
RU2009111391A (ru) 2010-10-10
KR101524880B1 (ko) 2015-06-01
CN103356997A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2248519A3 (en) Non-mucoadhesive film dosage forms
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
MY143795A (en) Tetrahydropyridoindole derivatives
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
IL190838A0 (en) Intranasal administration of rapid acting insulin
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
RS52457B (en) POWDER FORMULATION FOR VALGANCICLOVIR
NZ612063A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
MX2011000319A (es) Uso de rifalazil para tratar trastornos colonicos.
WO2008137054A3 (en) Composition for transmucosal delivery of polypeptides
DE602008006700D1 (es)
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
MX2013003523A (es) Composicion farmaceutica de dosis baja.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.

Legal Events

Date Code Title Description
FG Grant or registration